Alector Inc. Insider Trading

ALEC

Last 12 months

Insiders sold $1.02M and bought nothing on the open market.

3% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Feb 2020.

Net open-market

−$1.02M

0 buys · 18 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

Feb 2020

Feb 3, 2020

Get an email when ALEC's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 2 – 4	Grace Wong-Sarad Principal Accounting Officer	SoldNo plan 3 parts	9,446	$2.61 average	25K	8.2%	Form 4
Sep 3	Arnon Rosenthal Chief Executive Officer	SoldNo plan	72,606	$2.66	193K	2.2%	Form 4
Sep 3	Neil Lindsay Berkley CFO & Chief Business Officer	SoldNo plan	29,251	$2.66	78K	7.7%	Form 4
Jun 2 – 3	Grace Wong-Sarad Principal Accounting Officer	SoldNo plan 2 parts	9,184	$1.94 average	18K	8.8%	Form 4
Jun 2	Arnon Rosenthal Chief Executive Officer	SoldNo plan	87,216	$1.97	172K	2.8%	Form 4
Jun 2	Neil Lindsay Berkley CFO & Chief Business Officer	SoldNo plan	19,360	$1.97	38K	4.8%	Form 4
Apr 16	Grace Wong-Sarad Principal Accounting Officer	Sold10b5-1 plan	1,820	$2.65	5K	1.7%	Form 4
Mar 10	Grace Wong-Sarad Principal Accounting Officer	Sold10b5-1 plan	1,000	$2.65	3K	0.9%	Form 4
Mar 3	Grace Wong-Sarad Principal Accounting Officer	Sold10b5-1 plan	3,367	$2.08	7K	3.0%	Form 4
Mar 2	Neil Lindsay Berkley CFO & Chief Business Officer	SoldNo plan	29,649	$2.12	63K	7.9%	Form 4
Mar 2	Grace Wong-Sarad Principal Accounting Officer	SoldNo plan	8,071	$2.12	17K	6.8%	Form 4
Mar 2	Arnon Rosenthal Chief Executive Officer	SoldNo plan	81,864	$2.12	174K	2.7%	Form 4
Feb 26	Grace Wong-Sarad Principal Accounting Officer	Sold10b5-1 plan	4,079	$2.50	10K	3.3%	Form 4
Dec 5, 2025	Grace Wong-Sarad Principal Accounting Officer	Sold10b5-1 plan	4,753	$1.21	6K	3.7%	Form 4
Dec 3, 2025	Neil Lindsay Berkley Chief Bus Ofcr & Interim CFO	SoldNo plan	37,261	$1.12	42K	9.1%	Form 4
Dec 3, 2025	Grace Wong-Sarad Principal Accounting Officer	SoldNo plan	8,056	$1.12	9K	5.9%	Form 4
Dec 3, 2025	Sara Kenkare-Mitra President and Head of R&D	SoldNo plan	41,687	$1.12	47K	7.7%	Form 4
Dec 3, 2025	Arnon Rosenthal Chief Executive Officer	SoldNo plan	104,347	$1.12	117K	2.3%	Form 4
Sep 2, 2025	Grace Wong-Sarad Principal Accounting Officer	SoldNo plan	5,910	$2.50	15K	5.4%	Form 4
Sep 2, 2025	Neil Lindsay Berkley Principal Financial Officer	SoldNo plan	15,842	$2.50	40K	4.4%	Form 4
Sep 2, 2025	Sara Kenkare-Mitra President and Head of R&D	SoldNo plan	23,638	$2.50	59K	4.2%	Form 4
Sep 2, 2025	Arnon Rosenthal Chief Executive Officer	SoldNo plan	51,562	$2.50	129K	1.2%	Form 4
Aug 26, 2025	Paula Hammond Director	Sold10b5-1 plan	14,000	$2.36	33K	16%	Form 4
Jun 20, 2025	Kristine Yaffe Director	Sold10b5-1 plan	1,000	$1.44	1K	1.0%	Form 4
Jun 2, 2025	Marc Grasso Chief Financial Officer	SoldNo plan	16,488	$1.34	22K	5.3%	Form 4
Jun 2, 2025	Sara Kenkare-Mitra President and Head of R&D	SoldNo plan	23,890	$1.34	32K	4.5%	Form 4
Jun 2, 2025	Arnon Rosenthal Chief Executive Officer	SoldNo plan	52,087	$1.34	70K	1.7%	Form 4
Mar 3, 2025	Marc Grasso Chief Financial Officer	SoldNo plan	18,091	$1.47	27K	5.5%	Form 4
Mar 3, 2025	Sara Kenkare-Mitra President and Head of R&D	SoldNo plan	29,073	$1.47	43K	5.1%	Form 4
Mar 3, 2025	Arnon Rosenthal Chief Executive Officer	SoldNo plan	40,330	$1.47	59K	0.9%	Form 4
Mar 3, 2025	Gary Romano Chief Medical Officer	SoldNo plan	16,306	$1.47	24K	4.7%	Form 4
Dec 2, 2024	Marc Grasso Chief Financial Officer	SoldNo plan	16,489	$2.52	42K	4.7%	Form 4
Dec 2, 2024	Arnon Rosenthal Chief Executive Officer	SoldNo plan	52,172	$2.52	131K	1.2%	Form 4
Dec 2, 2024	Sara Kenkare-Mitra President and Head of R&D	SoldNo plan	26,500	$2.52	67K	4.5%	Form 4
Dec 2, 2024	Gary Romano Chief Medical Officer	SoldNo plan	14,892	$2.52	38K	4.1%	Form 4

Sep 2 – 4No plan
Grace Wong-Sarad
Principal Accounting Officer · sold 9,446 at avg $2.61
25K
8.2% of stake
Sep 3No plan
Arnon Rosenthal
Chief Executive Officer · sold 72,606 at $2.66
193K
2.2% of stake
Sep 3No plan
Neil Lindsay Berkley
CFO & Chief Business Officer · sold 29,251 at $2.66
78K
7.7% of stake
Jun 2 – 3No plan
Grace Wong-Sarad
Principal Accounting Officer · sold 9,184 at avg $1.94
18K
8.8% of stake
Jun 2No plan
Arnon Rosenthal
Chief Executive Officer · sold 87,216 at $1.97
172K
2.8% of stake
Jun 2No plan
Neil Lindsay Berkley
CFO & Chief Business Officer · sold 19,360 at $1.97
38K
4.8% of stake
Apr 1610b5-1 plan
Grace Wong-Sarad
Principal Accounting Officer · sold 1,820 at $2.65
5K
1.7% of stake
Mar 1010b5-1 plan
Grace Wong-Sarad
Principal Accounting Officer · sold 1,000 at $2.65
3K
0.9% of stake
Mar 310b5-1 plan
Grace Wong-Sarad
Principal Accounting Officer · sold 3,367 at $2.08
7K
3.0% of stake
Mar 2No plan
Neil Lindsay Berkley
CFO & Chief Business Officer · sold 29,649 at $2.12
63K
7.9% of stake
Mar 2No plan
Grace Wong-Sarad
Principal Accounting Officer · sold 8,071 at $2.12
17K
6.8% of stake
Mar 2No plan
Arnon Rosenthal
Chief Executive Officer · sold 81,864 at $2.12
174K
2.7% of stake
Feb 2610b5-1 plan
Grace Wong-Sarad
Principal Accounting Officer · sold 4,079 at $2.50
10K
3.3% of stake
Dec 5, 202510b5-1 plan
Grace Wong-Sarad
Principal Accounting Officer · sold 4,753 at $1.21
6K
3.7% of stake
Dec 3, 2025No plan
Neil Lindsay Berkley
Chief Bus Ofcr & Interim CFO · sold 37,261 at $1.12
42K
9.1% of stake
Dec 3, 2025No plan
Grace Wong-Sarad
Principal Accounting Officer · sold 8,056 at $1.12
9K
5.9% of stake
Dec 3, 2025No plan
Sara Kenkare-Mitra
President and Head of R&D · sold 41,687 at $1.12
47K
7.7% of stake
Dec 3, 2025No plan
Arnon Rosenthal
Chief Executive Officer · sold 104,347 at $1.12
117K
2.3% of stake
Sep 2, 2025No plan
Grace Wong-Sarad
Principal Accounting Officer · sold 5,910 at $2.50
15K
5.4% of stake
Sep 2, 2025No plan
Neil Lindsay Berkley
Principal Financial Officer · sold 15,842 at $2.50
40K
4.4% of stake
Sep 2, 2025No plan
Sara Kenkare-Mitra
President and Head of R&D · sold 23,638 at $2.50
59K
4.2% of stake
Sep 2, 2025No plan
Arnon Rosenthal
Chief Executive Officer · sold 51,562 at $2.50
129K
1.2% of stake
Aug 26, 202510b5-1 plan
Paula Hammond
Director · sold 14,000 at $2.36
33K
16% of stake
Jun 20, 202510b5-1 plan
Kristine Yaffe
Director · sold 1,000 at $1.44
1K
1.0% of stake
Jun 2, 2025No plan
Marc Grasso
Chief Financial Officer · sold 16,488 at $1.34
22K
5.3% of stake
Jun 2, 2025No plan
Sara Kenkare-Mitra
President and Head of R&D · sold 23,890 at $1.34
32K
4.5% of stake
Jun 2, 2025No plan
Arnon Rosenthal
Chief Executive Officer · sold 52,087 at $1.34
70K
1.7% of stake
Mar 3, 2025No plan
Marc Grasso
Chief Financial Officer · sold 18,091 at $1.47
27K
5.5% of stake
Mar 3, 2025No plan
Sara Kenkare-Mitra
President and Head of R&D · sold 29,073 at $1.47
43K
5.1% of stake
Mar 3, 2025No plan
Arnon Rosenthal
Chief Executive Officer · sold 40,330 at $1.47
59K
0.9% of stake
Mar 3, 2025No plan
Gary Romano
Chief Medical Officer · sold 16,306 at $1.47
24K
4.7% of stake
Dec 2, 2024No plan
Marc Grasso
Chief Financial Officer · sold 16,489 at $2.52
42K
4.7% of stake
Dec 2, 2024No plan
Arnon Rosenthal
Chief Executive Officer · sold 52,172 at $2.52
131K
1.2% of stake
Dec 2, 2024No plan
Sara Kenkare-Mitra
President and Head of R&D · sold 26,500 at $2.52
67K
4.5% of stake
Dec 2, 2024No plan
Gary Romano
Chief Medical Officer · sold 14,892 at $2.52
38K
4.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ALEC, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with ALEC

CompareIntrinsic value

CRSPCrispr Therapeutics AG

$51.78+3.57%40

LCTXLineage Cell Therapeutics Inc.

$1.03+1.98%10

ELUTElutia Inc.

$0.76-6.52%20

CRBUCaribou Biosciences, Inc.

$0.44-3.27%10

PTHSPelthos Therapeutics Inc.

$10.15-5.84%0

ACOGAlpha Cognition Inc.

$8.49+3.48%10

RLAYRelay Therapeutics Inc.

$18.03+3.38%40

TCRXTScan Therapeutics Inc.

$0.21+11.11%10

Held by ETFs

ALEC is in 8 US ETFs. The largest of them, with ALEC's weight in each:

Spot a number that looks wrong? Check it in ALEC's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ALEC

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.